日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer

新型 CHD1L 抑制剂作为癌症治疗策略的验证

Sophia Clune, Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, Jeffrey T Kearns, Timothy Kellett, Damilola Caleb Akintayo, Uday B Kompella, Daniel V LaBarbera

CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models

CHD1L 抑制剂 OTI-611 与化疗协同作用,增强抗肿瘤疗效并延长结直肠癌小鼠模型的生存期

Rita Sala, Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A Pike, Qiong Zhou, Wells A Messersmith, Daniel V LaBarbera

CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos

CHD1L 调节乳腺癌细胞存活,OTI-611 抑制该基因可阻碍 DNA 损伤反应并诱导 PARthanatos

Rita Sala, Hector Esquer, Timothy Kellett, Jeffrey T Kearns, Paul Awolade, Qiong Zhou, Daniel V LaBarbera

HTS discovery of PARP1-HPF1 complex inhibitors in cancer

HTS 发现癌症中 PARP1-HPF1 复合物抑制剂

Timothy Kellett, Rida Noor, Qiong Zhou, Hector Esquer, Rita Sala, Petra Stojanovic, Johannes Rudolph, Karolin Luger, Daniel V LaBarbera

Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21

氧化应激是 21 三体导致神经外胚层分化加速的候选机制

Kendra M Prutton, John O Marentette, Brice A Leifheit, Hector Esquer, Daniel V LaBarbera, Colin C Anderson, Kenneth N Maclean, James R Roede

Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L

首个致癌 CHD1L 抑制剂的设计、合成及生物学评价

Brett J Prigaro, Hector Esquer, Qiong Zhou, Laura A Pike, Paul Awolade, Xin-He Lai, Adedoyin D Abraham, Joshua M Abbott, Brock Matter, Uday B Kompella, Wells A Messersmith, Daniel L Gustafson, Daniel V LaBarbera

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes

针对分子膀胱癌亚型的高内涵药物发现

Sébastien Rinaldetti, Qiong Zhou, Joshua M Abbott, Florus C de Jong, Hector Esquer, James C Costello, Dan Theodorescu, Daniel V LaBarbera

High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog): Central Role for PTEN in 5-Azacytidine Protection Against Pathological Vascular Remodeling

高通量筛选鉴定出 DNMT1(DNA 甲基转移酶-1)抑制剂 5-氮杂胞苷是 PTEN(磷酸酶和张力蛋白同源物)的强效诱导剂:PTEN 在 5-氮杂胞苷预防病理性血管重塑中发挥着核心作用

Keith A Strand, Sizhao Lu, Marie F Mutryn, Linfeng Li, Qiong Zhou, Blake T Enyart, Austin J Jolly, Allison M Dubner, Karen S Moulton, Raphael A Nemenoff, Keith A Koch, Daniel V LaBarbera, Mary C M Weiser-Evans

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer

具有针对结直肠癌的临床前活性的首创致癌 CHD1L 抑制剂

Joshua M Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P Broneske, Sébastien Rinaldetti, Adedoyin D Abraham, Dominique A Ramirez, Paul J Lunghofer, Todd M Pitts, Daniel P Regan, Aik Choon Tan, Daniel L Gustafson, Wells A Messersmith, Daniel V LaBarbera

Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers

建立和鉴定四种新型甲状腺癌细胞系和PDX模型,这些细胞系和模型表达RET/PTC1重排、BRAFV600E或RASQ61R作为驱动基因

Rebecca E Schweppe ,Nikita Pozdeyev ,Laura A Pike ,Christopher Korch ,Qiong Zhou ,Sharon B Sams ,Vibha Sharma ,Umarani Pugazhenthi ,Christopher Raeburn ,Maria B Albuja-Cruz ,Philip Reigan ,Daniel V LaBarbera ,Iñigo Landa ,Jeffrey A Knauf ,James A Fagin ,Bryan R Haugen